Silo Pharma, Inc. (SILO)
About Silo Pharma, Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $72.1K
- Net income
- -$4.2M
- Total assets
- $7.6M
- Market cap
- $6.4M
- Gross margin
- 38.6%
- Operating margin
- -5937.0%
- Net margin
- -5863.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $72.1K
- Cost of revenue
- $44.3K
- Gross profit
- $27.8K
- Operating expenses
- $4.3M
- Operating income
- -$4.3M
- Net income
- -$4.2M
- EPS (basic)
- $-0.50
- EPS (diluted)
- $-0.50
Balance sheet
- Total assets
- $7.6M
- Current assets
- $7.4M
- Total liabilities
- $1.3M
- Current liabilities
- $650.2K
- Shareholders’ equity
- $6.3M
Cash flow
- Operating cash flow
- -$4.7M
- Investing cash flow
- $644.0K
- Financing cash flow
- $4.9M
- Net cash flow
- $842.9K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.4M
- EPS (diluted)
- $-0.5
- Shares outstanding
- 1.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 5, 2012
Silo Pharma, Inc. (SILO) Stock Price
- Reported a net loss of $4.2M in FY2025.
- Revenue declined 1% from FY2022 to FY2025.
- Gross margin of 38.6%, net margin -5863.5%.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Silo Pharma, Inc..
Write a review
News about Silo Pharma, Inc.
News & sentiment via Polygon.io
Silo Pharma, Inc.: frequently asked questions
Is Silo Pharma, Inc. an American company?
Silo Pharma, Inc. is a US-based company headquartered in Sarasota, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Silo Pharma, Inc. headquartered?
Silo Pharma, Inc. is headquartered in Sarasota, Florida, United States.
Is Silo Pharma, Inc. publicly traded?
Yes — Silo Pharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol SILO on the NASDAQ.
What does Silo Pharma, Inc. do?
Silo Pharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
